Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 21, 2024
CGD's Gyude Moore speaks with Nick O’Donohoe from British International Investment and Frank Aswani from the African Venture Philanthropy Alliance about balancing local and international focus, the impact of a "funding winter," and how the public and private sectors can fill the financing gap for bu...
Blog Post
February 21, 2024
So: how do donor governments actually use their subsidies to the private sector to support mitigation and development projects around the world? The process usually starts with a private company (the project sponsor) asking a development finance institution (DFI) like the World Bank Group’s Internat...
Blog Post
October 11, 2023
Budget support offers direct financing to a country’s treasury to create more “fiscal space” for public programs. It has constituted some 14 percent of ODA on average, increasing to over 20 percent in times of crisis. No aid modality is more controversial. Critics argue that, without earmarking fund...
Blog Post
August 30, 2023
There’s a representation problem in the fields of economics and research that has been well documented. As my colleagues have written about previously here and here, studies have shown that only 5 percent of papers in top journals study low- and middle-income countries (LMIC), and research output is...
Blog Post
July 27, 2023
Stephanie von Friedeburg of Citi and formerly the International Finance Corporation joins CGD’s Karen Mathiasen and Clemence Landers for a conversation on how to balance risk and impact in investment, why blended finance needs a rethink, and what mechanisms offer the most promising solutions to the ...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...